Prostate cancer clinical trials of the Southwest Oncology Group

ONCOLOGY

Volumn 11, Issue 8, 1997, Pages 1154-1163

  David Crawford, E ^a   Deantoni, Edward P ^b   Hussain, Maha ^c   Thompson, Ian M ^d   Coltman, Charles A ^e  

^a Division of Urology

^b UNIVERSITY OF COLORADO   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

^e Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; DIETHYLSTILBESTROL; DNA; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE SODIUM; ETOPOSIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SURAMIN; TOPOTECAN;

ANEMIA; CANCER HORMONE THERAPY; CLINICAL TRIAL; DIARRHEA; HUMAN; LIVER TOXICITY; MALE; ORCHIECTOMY; PLOIDY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 12644259504     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Crawford ED, Eisenberger MA, McLeod DG, et al: A continued trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-429, 1989.
2. Crawford ED, Hussain M, DeAntoni EP, et al: Southwest Oncology Group strategies in prostatic carcinoma. Semin Surg Oncol 11:1-5, 1995.
3. Denis L, Murphy GP: Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72:3888-3895, 1993.
4. Caubet J-F, Tosteson TD, Dong EW, et al: Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49:71-78, 1997.
5. 2 prostate cancer; important implications for future trials: Results of a cooperative intergroup study (INT.0036). Semin Oncol 21: 613-619, 1994.
6. DeAntoni EP, Crawford ED Pretreatment of metastatic disease: Prostate cancer in the older male. Cancer 74:2182-187, 1994.
7. Hillner BE, McLeod DG, Crawford ED, et al: Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 45:633-640, 1995.
8. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941.
9. Huggins C, Stevens Jr. RE, Hodges CW: Studies on prostatic cancer: II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209, 1941
10. Huggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer: Clinical features and urinary excretion of 17-ketosteroids and estrogens. Ann Surg 122:1031, 1945.
11. Akakura K, Bruchovsky N, Goldenberg SL, et al: Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 71:2782-2790, 1993.
12. Myers C, Cooper M, Stein C, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889M, 1992.
13. Murphy GP: Follow-up evaluation of national prostatic cancer project protocols and other studies. Urology 44(supp 6A):61-66, 1994.
14. Hussain M, Wolf M, Marshall E, Crawford ED, et al: Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase two chemotherapeutic trials for hormone refractory prostate cancer: A Southwest Oncology Group Report. J Clin Oncol 12:1868-1875, 1994.
15. Scher HI, Mazumdar M, Kelly WK: Clinical trials in relapsed prostate cancer. Defining the target. J Natl Cancer Inst 88:1623-1634, 1996.
16. Hussain M, Blumenstein BA, Eisenberger MA, et al: Southwest Oncology Group studies in hormone refractory prostate cancer. Semin Oncol 23:24-27, 1996.
17. Kucuk O, Blumenstein B, Moinpour C, et al: Phase II trial of Casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulation. A Southwest Oncology Group study (SWOG 9235). Proc Annu Meet Am Soc Clin Oncol 15:A618, 1996.
18. Pienta KJ, Redman B, Hussain M, et al: A phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994.
19. Kelly K, Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 149:607-609, 1993.
20. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993.
21. Dupont A, Gomez J-L, Cusan L, et al: Response to flutamide withdrawal in advanced prostate cancer in progression undercombination therapy. J Urol 150:908-913, 1993.
22. Sartor O, Cooper M, Weinberger M, et al: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 86:222-227, 1994.
23. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988.
24. Juan C, Hwang J, Lui A, et al: Tumor DNA topoisomerase I is encoded by a single copy gene that maps to chromosome region 20q12-13 2. Proc Natl Acad Sci 85:9810-9813, 1988.
25. Hudes GR, Kosierowski R, Greenberg R, et al: Phase II study of topotecan in metastatic hormone refractory prostate cancer. Invest New Drugs 13:235-240, 1995.
26. DeVita Jr. VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 3rd ed, p 1035. Philadelphia, JB Lippincott, 1989.
27. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45:8-30, 1995.
28. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:5-28, 1996.
29. DeAntoni EP, Crawford ED: Prostate cancer awareness week: Education, service and research in a community setting. Cancer 75:1874-1879, 1995
30. Catalona WJ, Bigg SW: Nerve sparing radical prostatectomy. Evaluation of results after 250 patients. J Urol 143:538-543, 1990.
31. Boges GE, McNeal JE, Redwine EA, et al: Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer 69:520-526, 1992.
32. Partin AW, Yoo J, Carter CB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993.
33. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1C) prostate cancer. JAMA 271:368-372, 1994.
34. Narayan P, Gajendran V, Taylor SP, et al: The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 46:205-212, 1995.
35. Pummer K, Crawford ED, Daneshgari F, et al: Hormonal pretreatment does not affect the final pathologic stage in locally advanced prostate cancer. Urology 44(suppl):38-42, 1994.
36. Labrie F, Cusan L, Gomez J-L, et al: Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing agonist. Urology 44(supp):29-37, 1994.
37. Soloway MS, Sharifi R, Wajsman Z, et al: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMo) prostate cancer J Urol 154:424-428, 1995.
38. Pilepich MV, Krall JM, al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-23, 1995.
39. Cheng WS, Frydenberg M, Bergstralh EJ, et al: Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 42:283-291, 1993.
40. Moinpour CM, Feigl P, Metch B et al: Quality of life end points in cancer clinical trials Review and recommendations. J Natl Cancer Inst 81:485-495, 1989.
41. Gotay CC, Korn EL, McCabe MS, et al: Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 84:575-579, 1992.
42. Gotay CC: Trial-related quality of life: using quality-of-life assessment to distinguish among cancer therapies. Monogr Natl Cancer Inst 20:1-6, 1996.
43. Moinpour CM: Costs of quality of life research in Southwest Oncology Group Trials. Monogr Natl Cancer Inst 20:11-16, 1996.
44. deVere White RW, Deitch AA, Tesluk H, et al: Prognostic significance of DNA ploidy in TA/T1 bladder cancer. A Southwest Oncology Group study. Urol Oncol, 1997(in press).
45. Fair WR, Aprikian AG, Cohen D, et al: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med 16:516-522, 1993.
46. Schulman CC, Sassine AM: Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol 24:450-455, 1993.
47. Watson RB, Soloway MS: Neoadjuvant hormonal treatment before radical prostatectomy. Semin Urol Oncol 14(suppl):48-55, 1996.
48. Feigl P, Blumenstein B, Thompson I, et al: Design of the prostate cancer prevention trial (PCPT). Cont Clin Trials 16:150-163, 1995.
49. Thompson I, Feigl P, Coltman C Chemoprevention of prostate cancer with finasteride. Prin Pract Oncol 10:1-18, 1996.
50. Moon TD, Brawer MK, Wilt TJ: Prostate intervention versus observation trial (PIVOT): A randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. Monogr Natl Cancer Inst 19:69-71, 1995.
51. Schwartz JS: Prostate cancer intervention versus observation trial: economic analysis in study design and conditions of uncertainty. Monogr Natl Cancer Inst 19:73-75, 1995.
52. Bruchovsky N, Snoek R, Rennie P, et al: Control of tumor progression by maintenance of apoptosis. Prostate 6(suppl):13-21, 1996.
53. Hussain M: Future directions in prostate cancer treatment: an oncologist's perspective. Prostate 6(suppl):26-30, 1996.
54. Hussain M: The biology of metastatic prostate cancer, in Peeling B (ed): Questions and Uncertainties in Prostate Cancer, pp 67-77. Oxford, United Kingdom, Blackwell Science, 1966.